Oak Hill Bio raises $32.5M Series A to advance Angelman syndrome therapy into Phase 3
What's the deal? Oak Hill Bio has closed US$21M Series A to advance rugonersen, a therapy for Angelman syndrome, into a pivotal Phase 3 clinical trial expected to begin mid-2026. The round was co-led by Balyasny Asset ManagementDealroom has a profile for this one. Try Dealroom →, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund.
Rugonersen is an antisense oligonucleotide designed to treat the root cause of Angelman syndrome by restoring production of the UBE3A protein in neurons. The therapy was originally developed by RocheDealroom has a profile for this one. Try Dealroom → and later acquired by Oak Hill Bio, which also recruited several members of the original development team.
Angelman syndrome is a rare neurodevelopmental disorder affecting roughly 30,000 diagnosed patients across the US and Europe's five largest markets. It causes severe cognitive and physical impairments, including developmental delays, epilepsy, and speech limitations — and no approved disease-modifying therapies currently exist.
Why now? The company says preclinical and Phase 1 data support rugonersen's potential as a best-in-class treatment. "We are well-positioned to advance rugonersen into a Phase 3 study in the middle of 2026," said chief executive officer Josh Distler.
Oak Hill Bio also bolstered its board alongside the raise. Doug Fambrough, founder of KCap Biotechnology Fund and former chief executive of RNA therapeutics pioneer Dicerna Pharmaceuticals, joined as a director. He's joined by venBio managing partner Rich Gaster and Sandeep Kulkarni, chief executive of Zura Bio and former co-founder of Tourmaline Bio.
What could go wrong? Late-stage neurological trials are expensive and complex, requiring substantial investment in patient recruitment, site management, and long-term follow-up. For a small company running on $32.5 million, execution risk is real — any delays or setbacks could force it back to the fundraising table before reaching a regulatory filing.
The Angelman syndrome treatment landscape is also evolving. If competing programmes advance faster or show stronger data, rugonersen's commercial prospects could narrow even with positive Phase 3 results.
The signal: Oak Hill Bio's Series A reflects a growing biotech model in which specialised firms acquire promising rare disease assets that larger pharma companies have deprioritised, then advance them with dedicated capital and focused teams. The investor mix here is notable — Balyasny Asset Management and Janus Henderson Investors are large, diversified investment funds rather than typical early-stage biotech backers, suggesting confidence that the asset-acquisition playbook can deliver returns even at the Phase 3 stage.
Read more: citybiz.co
